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LETTERS TO THE EDITORThe LCR at the IKBKG Locus
Is Prone to Recombine
To the Editor: We read with great interest the paper by
Vandewalle et al.1 that appeared in the December 11,
2009, issue of AJHG. The manuscript reports on a 0.3 Mb
recurrent but variable copy number gain in the Xq28
region that is found to be associated with mental retarda-
tion (MR). This paper is of special interest to us as scientists
working in the ﬁeld of Xq28-linked disease. However, we
would like to make a few comments, which we feel would
contribute to themessage of the paper. The authors suggest
that the effect of the copy number gain is most likely due
to the increased expression of GDI1. We think it is impor-
tant that other genes in the region, and in particular
IKBKG, be considered for their potential role in MR. In
addition, we think that critical previous work on the
LCRs L1 and L2 was not included.
As reported, the 0.3 Mb copy number gain in Xq28
contains 18 genes (although 19 genes are listed in Table 1).
Vandewalle et al.1 provided data on the increased expres-
sion of GDI1 (GenBank NM_001493 [MIM 300104]).
However, they did not analyze the mRNA expression of
the other genes in the duplicated region, and abnormal
expression of one or several of these genes might con-
tribute to the mental handicap observed in the affected
families. Of particular note, the phenotypic features dis-
cussed in the paper are common to inactivation of other
Xq28 brain disease genes, such as IKBKG (MIM 300248),
in which, similar to GDI1, loss-of-function mutations are
associated with mental retardation.
IKBKG (GenBank NM_003639.3), also called nuclear
factor kappaB (NF-kB) essential modulator (NEMO/IKK-
gamma), encodes for NEMO/IKKgamma, a protein that
is generally recognized to have an essential role in the
NF-kB signaling. The NF-kB pathway controls several
cellular and developmental processes, and the timely acti-
vation and inactivation of this signaling is essential for
NF-kB to function in a controlled manner. Indeed, the
NEMO/IKKgamma protein, because of its proven crucial
role in the pathway, is tightly regulated at posttranslation
levels by sequential protein modiﬁcation,2 as well as at
transcriptional levels by multiple regulatory regions.3,4 In
addition, the IKBKG gene is highly expressed in the brain
and has a well-documented role in neuronal plasticity
and central nervous system (CNS) development.5,6 It has
been reported that an imbalanced function of IKBKG
affects the regulation of NF-kB signaling in this tissue,5
and when NF-kB is hyperactivated or repressed, a defect
of neurite growth in a speciﬁc subset of neurons is
observed.6 It is noteworthy that such a role of the NF-kB
pathway in CNS development was conﬁrmed in three
reports appearing in the same issue of AJHG, in which650 The American Journal of Human Genetics 86, 650–653, April 9, 2Philippe et al.,7 Mochida et al.,8 and Mir et al.9 identiﬁed
an NF-kB signaling defect as a cause of MR.
The role of IKBKG in the CNS is strongly supported by
human genetic data. Loss-of-function mutations of IKBKG,
although lethal in males, cause incontinentia pigmenti
(IP [MIM 308300]) in females, a neurocutaneous disorder
often associated with mental retardation, psychomotor
delay, seizure, spastic paresis, andmicrocephaly. IP patients
may also present cortical necrosis, several white matter
abnormalities, hypoplasia of the corpus callosum,
etc.10,11 A heterozygous exon 4_10 IKBKG deletion is
the major genetic defect in IP, caused by recombination
between two consecutive medium reiterated 67B
(MER67B) repeats, located in intron 3 and downstream to
exon 10 of the gene, respectively.12 Nevertheless, missense
mutations in IKBKG have also been found in association
with severe mental handicap.13 Thus, the notion that
IKBKG is involved in MR is generally recognized, and the
gene was added to the list of MR genes in 2005.14
In addition, we would like to bring attention to previous
work on the two distal LCRs discussed in the manuscript
by Vandewalle et al.1 The authors reported that the LCRs
(named L1 and L2 on page 809) recombine to cause the
copy-number gain observed in their four MR families.
Although the authors correctly reported that the two
LCRs share a high sequence homology, citing the paper
of Aradhya et al.,15 they failed to note the presence of
IKBKG and its truncated pseudogene copy (from exon 3
to 10) within the two repeats. It would be of interest for
people working in clinical genetics to know whether any
of the putative mechanistic recombination affected the
IKBKG gene and how many copies of this gene are present
in the recombinant alleles.
Furthermore, the notion that the L1 and L2 sequence
homology causes recombination was extensively docu-
mented in the previous reports. Aradhya et al.,15 cited by
Vandewalle et al.,1 detected evidence for sequence
exchange between the L1 and L2 copies, pointing out
that because the two LCR copies are in opposite orienta-
tion, inversions might be responsible for their homoge-
neity. More recently, we reported additional proof of the
ability of the LCRs L1 and L2 to recombine.16 Indeed, we
observed in IP families a recombination event produced
by non-allelic-homology recombination (NAHR) between
two LCRs that repositioned an exon4_10 deletion from
the pseudogene (IKBKGP, GenBank NG_001576) to the
IKBKG gene, thereby causing the IP disease (Figure 1).
Vandewalle et al.1 stated that they were unable to clone
the breakpoint junctions because of the very high
sequence homology between the LCR subunits and the
multiple rearrangements that take place between them.
We would like to suggest that the authors review our
work in which, by using a PCR-based strategy, we map-
ped the breakpoint in the IP family carrying IKBKG010
Figure 1. An Example of NAHR between
L1 and L2 Causing a Pathological Allele Is
Reported: The Case Represents the IKBKG
Locus in an IP Family
The unaffected mother (I:2) carrying the
exon4_10 deletion in the IKBKGP pseudo-
gene is reported. The IP patient (II:1)
carrying the pathogenic deletion in the
gene (exon4_10 deletion) is reported.
The misalignment between the two
LCRs, L1 and L2, produces the intrachro-
mosomal recombination transferring the
exon4_10 del deletion (DExon4_10) from
the pseudogene to the gene in the
recombinant allele.recombinant alleles, which occur by NAHR between L1
and L2.16 We were able to establish that all recombination
between LCRs L1 and L2 occur in the MER67B repeats
located in intron 3 and downstream exon 10 of the IKBKG
gene. Notably, other recurrent intrachromosomal recombi-
nation, occurring between two MER67B repeats located
within the one individual copy of the LCR, may produce
microdeletion-microduplication in the IKBKG gene and
pseudogene.16,17
In conclusion, the presence of high-repetitive DNA
sequence families, LCRs, and a nonprocessed pseudogene
sequence in the Xq28 region is known to enhance homolo-
gous recombination. Several previous studies have pointed
out the ability of L1 and L2 copies to recombine giving rise
to both pathological and nonpathological structural vari-
ants of the human genome or copy number variations
(CNVs). The recombinant alleles reported by Vandewalle
et al.1 ﬁt verywell with these previous ﬁndings. In addition,
wewonderwhether anyother gene in theduplicated region
may play a role in the MR phenotype described by the
authors. In particular, we favor the analysis of IKBKG, ﬁrst
of all because it is located exactly in the recombination
region, and second, because its nature suggests that any
upregulation or decreased expression may cause cellular
dysfunction and thus disease in a tissue-speciﬁc manner.18
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To the Editor: The authors’ comments consist of two parts,
to which we will reply separately.
1) The authors state that next to GDI1, overexpression of
other genes present within the recurrent aberration should
be taken into account as well to explain the MR phenotype
in our families. In particular, the IKBKG gene is a candidate
because mutations have been implicated in IP, often asso-
ciated with neurological abnormalities, and because the
NF-kB pathway has been linked to MR. We completely
agree with a prominent role for the IKBKG gene and its
pathway in neurological disorders and we have taken this
gene seriously into account for a role in the MR phenotype
of our families. However, we identiﬁed a 190 kb duplica-
tion, which overlaps our recurrent aberration, in a female
patient as well as her normal father. This ﬁnding is
described on page 812 of our paper1 and the position of
this polymorphic duplication is illustrated in Figure 2
(horizontal striped bar). This benign copy number variant
includes, among others, IKBKG, which demonstrates that
at least a duplication of this gene does not cause a patholog-
ical condition. Because IKBKG is duplicated in affected
males of our family 4, we excluded it as a candidate gene.
We do mention that we still have to be careful with this
‘‘rejection.’’ We agree, however, that in the sentence onpage 819 ‘‘Moreover, the role of other genes within the aberra-
tion, such as UBL4A and FAM3A, cannot be excluded even
though the apparent 190 kb copy-number polymorphism identi-
ﬁed in a normal male individual seems to exclude a contribution
of a double dosage of both genes in family 4,’’ the IKBKG gene
should have been included as well. Of the remaining genes
in the nonoverlapping aberrant region, we did check brain
expression for all genes. For those with the highest expres-
sion (FLNA, RPL10, ATP6AP1, and GDI1), we checked their
expression levels in patient-derived cell lines. So we did not
focus on GDI1 alone but proposed this gene as the most
likely candidate gene, which is clearly discussed.
2) The authors would have liked us to putmore emphasis
on the recombination events that occur between the two
oppositely oriented LCRs, L1 and L2, and the consequences
these might have on the IKBKG gene. In our study, the aim
was not to describe the NAHR events that occur between
LCR partners (K1 and K2, or L1 and L2). We clearly point
to the occurrence of recombination events (see page 816
‘‘. multiple possible NAHR-driven inversion events that could
have taken place between the subunits of each set’’) that prob-
ably resulted in homogeneity of the entire LCR. Because
IKBKG was not regarded as a candidate dosage-sensitive
gene for the MR phenotype, and because our male patients
as well as their carrier mothers do not show characteristics
features of IP, we did not further investigate the IKBKG010
